Full-Time

Director – Pharmaceutical Development

Fulcrum Therapeutics

Fulcrum Therapeutics

51-200 employees

Clinical-stage biopharma addressing genetically defined diseases

Compensation Overview

$240k/yr

Cambridge, MA, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • PhD with 10 years or MS with equivalent years of experience. Professional background in Pharmaceutical Sciences (preferred) or Chemical Engineering
  • Proven track record and leadership in phase-appropriate drug development through pivotal studies (required) and approval (preferred)
  • Subject matter expert in material science aspects of dosage forms and drug delivery, with emphasis on solid oral dosage forms; strong knowledge in Dissolution, Biopharmaceutics and Pharmacokinetics
  • Well versed in Regulatory Chemistry, Manufacturing, and Controls and International Council for Harmonisation guidance, including exposure to U.S. Food and Drug Administration interactions (e.g. via preNDA meetings)
  • Strong written and oral communication skills; highly effective collaborator with customers in ClinOps and Commercial
  • Ability to hire and recruit staff, including key contractors and consultants
  • Positive work presence; ability to respond to stress and ambiguity with humor
Responsibilities
  • Lead all strategic and tactical aspects of drug product development at Fulcrum
  • Design and execute pharmaceutical product development plans for all development programs in accordance with corporate goals
  • Collaborate with colleagues in Drug Substance, Analytical, ClinOps, QA, and Regulatory CMC to ensure plans are cross-functional, phase-appropriate, and on time
  • Lead pharmaceutical development for the pociredir program, including CTM for pivotal clinical studies, pre-validation studies, validation plans, and commercial launch supply
  • Lead and manage product development, technology transfer, and clinical manufacturing activities at contract manufacturing organizations (CMOs), assuring compliance with Regulatory and Quality requirements
  • Lead pediatric formulation development efforts, as required
  • Review and approve a broad spectrum of documents (MBRs, Specifications, Protocols, Reports, etc.) at CMOs
  • Generate, review and approve documents related to Drug Product (formulation, process development, manufacturing, etc.) for Regulatory submissions (IND/IMPD and NDA/MAA)

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on genetically defined rare diseases. It uses a proprietary product engine to systematically identify and validate cellular drug targets and to modulate gene expression in order to address the root causes of these diseases. The company collaborates with other industry players, such as MyoKardia, to discover targeted therapies for genetic cardiomyopathies. Its business model centers on developing and commercializing therapies and earning revenue through product sales, partnerships, and licensing agreements. Unlike competitors that may have broader approaches, Fulcrum concentrates on precise genetic targets and gene-expression modulation to tackle specific rare diseases, aiming to bring real clinical benefits to patients while pursuing collaborations to expand its pipeline.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA engagement on HbF surrogate endpoint could accelerate pociredir registration pathway significantly.
  • $333.3M cash runway into 2029 funds potential Phase 3 initiation and commercialization.
  • Open-label extension trial generates long-term safety and durability data supporting future registration.

What critics are saying

  • Vertex's approved casgevy dominates SCD market, sidelining pociredir's small-molecule approach competitively.
  • FDA rejection of HbF surrogate endpoint forces full Phase 3 outcomes trial, depleting cash.
  • CFO Alan Musso's 2026 retirement disrupts financial oversight during critical Phase 2/3 transition.

What makes Fulcrum Therapeutics unique

  • Pociredir achieved 12.2% absolute HbF increase at 20mg dose in Phase 1b PIONEER trial.
  • Proprietary gene expression platform targets root causes of genetically defined rare diseases systematically.
  • Seven of 12 patients experienced zero vaso-occlusive crises with no serious adverse events.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Fulcrum Therapeutics who can refer or advise you

Benefits

Flexible Work Hours

Hybrid Work Options

Remote Work Options

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

PTO/vacation

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

-1%

2 year growth

-3%
The Manila Times
Jan 7th, 2026
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Fulcrum Therapeutics to participate in the 44th Annual J.P. Morgan Healthcare Conference. CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) - Fulcrum Therapeutics, Inc.(R)(Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics' website for at least 30 days following the presentation. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Quiver Quantitative
Dec 10th, 2025
Fulcrum Therapeutics prices $175M public offering at $13.50 per share for sickle cell research

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, has priced its public offering of 11.85 million common shares at $13.50 each and pre-funded warrants for 1.11 million additional shares at $13.499 per warrant. The offering is expected to raise approximately $175 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to 1.94 million additional shares. Proceeds will support general corporate purposes, including research and development for clinical programmes, particularly pociredir, its lead treatment for sickle cell disease. J.P. Morgan, Leerink Partners and Cantor are serving as book-running managers, with Oppenheimer & Co. and Truist Securities also participating. The offering is expected to close on 11 December 2025, subject to customary conditions.

GlobeNewswire
Dec 10th, 2025
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company...

The Manila Times
Nov 3rd, 2025
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Fulcrum Therapeutics to present new clinical data from the PIONEER trial of pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting. Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be Hosted Onsite on Sunday, December 7 CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) - Fulcrum Therapeutics, Inc.(R)(the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that new data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting. Additionally, Fulcrum will present preclinical data highlighting its calmodulin pathway modulator program for the potential treatment of bone marrow failure syndromes. "We are looking forward to presenting new clinical data from the PIONEER trial at ASH, including full data from the 12 mg dose cohort and initial data from the 20 mg dose cohort," said Alex C. Sapir, Fulcrum's President and Chief Executive Officer. "These data will further characterize pociredir's potential as a disease-modifying therapy for sickle cell disease, and we look forward to discussing the results in greater detail during our investor event at ASH." Title: Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b PIONEER study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness

Stem Cell Therapy TV
Feb 7th, 2025
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Fulcrum Therapeutics to participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.